Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology-Reference-Cited by-同舟云学术

Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology

Published:2019-03-01 Issue:3 Volume:5 Page:402
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Parseghian Christine M.¹,Tam Alda L.²,Yao James¹,Ensor Joe³,Ellis Lee M.⁴,Raghav Kanwal¹,Overman Michael J.¹

Affiliation:

1. Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston

2. Division of Diagnostic Imaging, Department of Interventional Radiology, The University of Texas M.D. Anderson Cancer Center, Houston

3. Houston Methodist Cancer Center, Houston Methodist Research Institute Methodist, Houston, Texas

4. Division of Surgery, Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/3/402/17345675/jamaoncology_parseghian_2018_br_180016.pdf

Reference12 articles.

1. Biomarkers in early clinical trials: the committed and the skeptics.;Banerji;Clin Cancer Res,2008

2. Trends in the use and role of biomarkers in phase I oncology trials.;Goulart;Clin Cancer Res,2007

3. Underreporting of research biopsies from clinical trials in oncology.;Parseghian;Clin Cancer Res,2017

4. Factors associated with failure to publish large randomized trials presented at an oncology meeting.;Krzyzanowska;JAMA,2003

5. The fate of abstracts submitted to a cancer meeting: factors which influence presentation and subsequent publication.;De Bellefeuille;Ann Oncol,1992

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials;Cancer Research Communications;2024-08-01

2. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer;Cancer Cell;2024-05

3. The landscape of investigator‐initiated oncology trials conducted in mainland China during the past decade (2010–2019);Cancer Innovation;2023-02

4. Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?;Journal of Clinical Oncology;2023-01-10

5. An Expanded Role for IRBs in the Oversight of Research Biopsies;Ethics & Human Research;2022-09